关键词: 早期乳腺癌, 21 基因, 复发风险评分, 激素受体阳性, 治疗决策

Abstract:

 Objective To analyses the utility of 21-gene recurrence score assay in treatment decisions for women with hormonal-receptor positive （HR+） and HER2-early breast cancer （EBC）. Methods A total of 29 female patients with HR + EBC who had been hospitalized in Jiangmen Central Hospital, from January 2016 to January 2017, were divided into low risk group and intermediate/high risk group according to the recurrence score. The general clinical pathological characteristics and the treatment recommendations before and after 21-gene recurrence score assay in each groups were compared. Results Association analysis showed that recurrence score was no relative with ages, menopausal status, tumor size, histopathological grade and vascular invasion, but significantly associative with Ki-67（P=0.027）. About 18 patients （62.0%） recommended endocrine therapy combined with adjuvant chemotherapy before 21-gene recurrence score assay. The proportion of patients recommended chemotherapy decreased from 62.0% pretest to 24.1% post?test（McNemar’s test, P=0.001）. 11 patients （37.9%）changed treatment decisions to endocrine therapy alone. Conclusion Using 21?gene recurrence score assay can significantly change treatment decisions and make an overall reduction in chemotherapy use in women with hormonal?receptor positive early breast cancer.

Key words: early breast cancer, 21?gene, recurrence score, hormonal?receptor positive, treatment decisions